Navigation Links
Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
Date:1/15/2008

SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) announced today that it priced an offering of 800,000 shares of CTI new common shares. This share issue will equate to approximately 1.2% percent of CTI's market capitalization. The offering is expected to close on Wednesday, January 16, and to raise approximately $1,270,000 (euros 856.000). The shares will be sold to Societe Generale, pursuant to the Step-Up Equity Financing Agreement entered into by CTI and Societe Generale, dated June 21, 2006 as amended. CTI intends to use the net proceeds for general corporate purposes, including the preparation and filing of new drug applications and preclinical and clinical trials.

A shelf registration statement relating to the shares issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. A listing prospectus relating to this offering was also published in Italy on January 14, 2008, and the shares sold in the offering are registered in Italy pursuant to that listing prospectus. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, there is a risk that the transaction referred to in this press release may be delayed or may not ultimately close if certain conditions set forth in the Step-Up Equity Financing Agreement are not satisfied. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian or Susan Callahan

T: 206.272.4343 or 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, ... Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon Media is ... most widely referenced global news source in the human capital sector. , “It is ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):